Syndax Pharmaceuticals
SNDX
47 hedge funds and large institutions have $102M invested in Syndax Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 1 closing their positions.
2,000% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 1
74% more funds holding
Funds holding: 27 → 47 (+20)
19% less capital invested
Capital invested by funds: $126M → $102M (-$23.8M)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$9.85M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.33M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.7M |
| 4 |
Jennison Associates
New York
|
+$1.05M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$689K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$3.84M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.1M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$686K |
| 4 |
Millennium Management
New York
|
-$456K |
| 5 |
Goldman Sachs
New York
|
-$353K |
SNDX Hedge Fund Activity: Q2 2016 in Review
47 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q2 2016, worth a combined $102M — down 19% from $126M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new SNDX positions and 1 closed out — a net gain of 20 holders — while 8 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock Advisors, adding an estimated $9.85M. The largest seller was Tiverton Asset Management, cutting an estimated $3.84M.
- 47 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q2 2016, up from 27 in Q1 2016.
- Funds reported $102M of Syndax Pharmaceuticals stock for Q2 2016, down 19% quarter-over-quarter.
- 21 funds opened new Syndax Pharmaceuticals positions in Q2 2016 and 1 closed out, a net change of +20 holders.
- The largest Syndax Pharmaceuticals buyer in Q2 2016 was BlackRock Advisors, an estimated $9.85M added.
- The largest Syndax Pharmaceuticals seller in Q2 2016 was Tiverton Asset Management, an estimated $3.84M sold.
Based on aggregated 13F filings for Q2 2016.